| Preface to the fourth edition |
|
v | |
| Acknowledgements |
|
vi | |
|
Chapter 1 Getting a drug into the body: absorption |
|
|
1 | (8) |
|
Chapter 2 Getting a drug to its site of action: distribution |
|
|
9 | (6) |
|
Chapter 3 Inactivating drugs: phase 1 drug metabolism |
|
|
15 | (8) |
|
Chapter 4 Phase 2 drug metabolism and methods of excretion |
|
|
23 | (8) |
|
Chapter 5 The concept of a drug's half-life (t1/2): an estimate of the rate of elimination of different drugs |
|
|
31 | (4) |
|
Chapter 6 Receptor function and Intercellular signalling |
|
|
35 | (8) |
|
Chapter 7 The central role of receptors in drug action |
|
|
43 | (6) |
|
Chapter 8 Drugs that block enzymes: understanding NSAID therapy in inflammation |
|
|
49 | (8) |
|
Chapter 9 The principal targets for drug action |
|
|
57 | (8) |
|
Chapter 10 Calcium Ion for the Prescriber |
|
|
65 | (8) |
|
DRUGS AND THE CENTRAL NERVOUS SYSTEM |
|
|
73 | (48) |
|
Chapter 11 Introduction to drugs in the central nervous system |
|
|
75 | (8) |
|
Chapter 12 CNS drugs whose action is (a) understood, (b) unknown/speculative |
|
|
83 | (2) |
|
Chapter 13 The actions of CNS drugs used to treat anxiety, insomnia and life-threatening status epilepticus |
|
|
85 | (6) |
|
Chapter 14 Drugs used to treat Parkinsonism |
|
|
91 | (4) |
|
Chapter 15 Pain and analgesics |
|
|
95 | (6) |
|
Chapter 16 How anti-emetic drugs work |
|
|
101 | (2) |
|
Chapter 17 Antipsychotic drugs |
|
|
103 | (4) |
|
Chapter 18 Antidepressant drugs |
|
|
107 | (4) |
|
Chapter 19 Anti-epileptic drugs |
|
|
111 | (2) |
|
Chapter 20 Drugs of abuse: hallucinogens and CNS stimulants |
|
|
113 | (6) |
|
Chapter 21 Alzheimer's disease |
|
|
119 | (2) |
|
DRUG TOPICS OF SPECIAL IMPORTANCE |
|
|
121 | (67) |
|
Chapter 22 How the many antidiabetic drugs work |
|
|
123 | (6) |
|
Chapter 23 Treating severe chronic inflammation |
|
|
129 | (6) |
|
Chapter 24 The scientific basis of prescribing for the elderly |
|
|
135 | (8) |
|
Chapter 25 Antibacterial action and bacterial resistance |
|
|
143 | (10) |
|
Chapter 26 How to prevent adverse drug interactions -- ADIs |
|
|
153 | (12) |
|
Chapter 27 How to predict and avoid adverse drug reactions to single drugs -- ADRs |
|
|
165 | (8) |
|
Chapter 28 Why consider a practice formulary? |
|
|
173 | (4) |
|
Chapter 29 Getting new drugs to market: licensing medicines for human use |
|
|
177 | (6) |
|
Chapter 30 The problem of patients' non-compliance with their medication -- `non-concordance' |
|
|
183 | (5) |
| Conclusion |
|
188 | (1) |
| Prescribing safely: a checklist for every prescription |
|
189 | (1) |
| Index |
|
190 | |
Biežāk uzdotie jautājumi par e-grāmatām